VEA
BBIO icon

Virtus ETF Advisers’s BridgeBio Pharma BBIO Stock Holding History

Virtus ETF Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,637
Closed -$347K – 463
2024
Q4 		$347K Buy
12,637
+1,280
+11% +$33.1K 0.14% 203
2024
Q3 		$289K Hold
11,357
– – 0.14% 231
2024
Q2 		$288K Buy
11,357
+746
+7% +$20.4K 0.14% 232
2024
Q1 		$328K Buy
10,611
+1,527
+17% +$51.9K 0.17% 221
2023
Q4 		$367K Sell
9,084
-8,934
-50% -$268K 0.23% 179
2023
Q3 		$475K Sell
18,018
-2,327
-11% -$66K 0.29% 174
2023
Q2 		$350K Sell
20,345
-11,903
-37% -$179K 0.21% 152
2023
Q1 		$535K Buy
32,248
+567
+2% +$6.61K 0.29% 130
2022
Q4 		$241K Sell
31,681
-4,494
-12% -$43K 0.13% 308
2022
Q3 		$360K Buy
36,175
+529
+1% +$5.5K 0.14% 248
2022
Q2 		$324K Buy
35,646
+31,589
+779% +$264K 0.12% 261
2022
Q1 		$41K Sell
4,057
-247
-6% -$2.54K 0.02% 366
2021
Q4 		$72K Buy
4,304
+968
+29% +$41K 0.03% 375
2021
Q3 		$156K Sell
3,336
-173
-5% -$9.27K 0.07% 332
2021
Q2 		$214K Sell
3,509
-1,393
-28% -$79.6K 0.09% 290
2021
Q1 		$302K Buy
4,902
+82
+2% +$5.37K 0.13% 240
2020
Q4 		$343K Sell
4,820
-5,933
-55% -$286K 0.14% 174
2020
Q3 		$403K Sell
10,753
-1,458
-12% -$45.9K 0.21% 167
2020
Q2 		$398K Buy
12,211
+2,351
+24% +$71.6K 0.19% 196
2020
Q1 		$286K Sell
9,860
-1,435
-13% -$44.5K 0.12% 230
2019
Q4 		$396K Buy
+11,295
New +$313K 0.06% 259

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Virtus ETF Advisers's BBIO Position: Q1 2025 in Review

Virtus ETF Advisers sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 12,637 shares — an estimated $347K sold.

Virtus ETF Advisers first reported a position in BBIO in Q4 2019 and held it in 21 quarters. The position peaked at $535K in Q1 2023. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

  • Virtus ETF Advisers reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 12,637 BridgeBio Pharma shares in Q1 2025, an estimated $347K.
  • Virtus ETF Advisers first reported a position in BridgeBio Pharma in Q4 2019 and held it in 21 quarters.
  • Virtus ETF Advisers's BridgeBio Pharma position peaked at $535K in Q1 2023.
  • 304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.